150 related articles for article (PubMed ID: 17587722)
1. Price disparity of percutaneous coronary intervention devices in Japan and the United States in 2006.
Yasunaga H; Ide H; Imamura T; Ohe K
Circ J; 2007 Jul; 71(7):1128-30. PubMed ID: 17587722
[TBL] [Abstract][Full Text] [Related]
2. Current disparities in the prices of medical materials between Japan and the United States: further investigation of cardiovascular medical devices.
Yasunaga H; Ide H; Imamura T
J Cardiol; 2007 Feb; 49(2):77-81. PubMed ID: 17354581
[TBL] [Abstract][Full Text] [Related]
3. Impact of change in the price of percutaneous coronary intervention devices on medical expenses.
Kuroda N; Kobayashi Y; Desai K; Costantini C; Kobayashi M; Komuro I
Circ J; 2003 Jul; 67(7):576-8. PubMed ID: 12845178
[TBL] [Abstract][Full Text] [Related]
4. Price differences between Japan and the US for medical materials and how to reduce them.
Ide H; Yasunaga H; Imamura T; Ohe K
Health Policy; 2007 Jun; 82(1):71-7. PubMed ID: 17028042
[TBL] [Abstract][Full Text] [Related]
5. How firms set prices for medical materials: a multi-country study.
Ide H; Mollahaliloglu S
Health Policy; 2009 Sep; 92(1):73-8. PubMed ID: 19342115
[TBL] [Abstract][Full Text] [Related]
6. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
Chino M; Sasaki T
Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
[No Abstract] [Full Text] [Related]
7. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
[TBL] [Abstract][Full Text] [Related]
8. Long-term resource use and cost of percutaneous transluminal coronary angioplasty versus stenting in the elderly: a retrospective claims data analysis.
Subramanian S; Khandker RK; Roth D
Value Health; 2003; 6(5):534-41; discussion 532-3. PubMed ID: 14627059
[TBL] [Abstract][Full Text] [Related]
9. [Cost analysis of procedural fee for percutaneous transluminal coronary angioplasty at six Japanese hospitals].
Chino M
J Cardiol; 2001 Feb; 37(2):83-90. PubMed ID: 11255699
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with reuse of coronary angioplasty catheters in the United States.
Browne KF; Maldonado R; Telatnik M; Vlietstra RE; Brenner AS
J Am Coll Cardiol; 1997 Dec; 30(7):1735-40. PubMed ID: 9385901
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of angioplasty salvage techniques, with an emphasis on coronary stents: a method incorporating costs, revenues, clinical effectiveness and payer mix.
Vaitkus PT; Witmer WT; Brandenburg RG; Wells SK; Zehnacker JB
J Am Coll Cardiol; 1997 Oct; 30(4):894-900. PubMed ID: 9316515
[TBL] [Abstract][Full Text] [Related]
12. The systems, the operators, the patients: the impact of PTCA equipment on health care cost.
Talley JD; Mauldin PD
J Interv Cardiol; 1995 Aug; 8(4):343-4. PubMed ID: 10155246
[No Abstract] [Full Text] [Related]
13. Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care.
Mahieu J; De Ridder A; De Graeve D; Vrints C; Bosmans J
Acta Cardiol; 2007 Aug; 62(4):355-65. PubMed ID: 17824296
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
[TBL] [Abstract][Full Text] [Related]
15. [Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
Fricke FU; Silber S
Herz; 2005 Jun; 30(4):332-8. PubMed ID: 15965811
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
Polanczyk CA; Wainstein MV; Ribeiro JP
Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
[TBL] [Abstract][Full Text] [Related]
17. Reimbursement pricing for new medical devices in Japan: Is the evaluation of innovation appropriate?
Tamura M; Nakano S; Sugahara T
Int J Health Plann Manage; 2019 Apr; 34(2):583-593. PubMed ID: 30549085
[TBL] [Abstract][Full Text] [Related]
18. Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions.
Vaitkus PT
Am Heart J; 1999 Feb; 137(2):258-63. PubMed ID: 9924159
[TBL] [Abstract][Full Text] [Related]
19. Medicare's Hospital Compare quality reports appear to have slowed price increases for two major procedures.
Dor A; Encinosa WE; Carey K
Health Aff (Millwood); 2015 Jan; 34(1):71-7. PubMed ID: 25561646
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
